title: [Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance].
abstract: OBJECTIVE
  Clinical observation was conducted on the resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) gefitinib (Iressa) therapy for advanced non-small cell lung cancer (NSCLC) patients.
  
  
  METHODS
  Ninety-three NSCLC patients in our hospital, showing effective or stable condition after 6-month previous gefitinib therapy, were included in this investigation. Among the patients, 94.6% of them were suffering from adenocarcinoma. The percentage of female is 79.6%; the percentage of non-smoking is 80.6%. During the therapy period, follow-up was preformed every 2 months.
  
  
  RESULTS
  Among the 93 patients, median therapy time was 16 months (range: 8 to 70 months), and 21.5% (20/93) of them had received therapy for more than 2 years, while 8.6% (8/93) had received that for more than 3 years. The progression included 80% (72/90) for intrapleural progression, 38.9% (35/90) for primary tumor plus recurrence after sugary especially, 51.1% (46/90) for intrapulmonary metastasis, 25.6% (23/90) for pleural metastasis, 30% (30/90) for intracranial progression and 15.6% (14/90) for intraperitoneal progression.
  
  
  CONCLUSIONS
  Resistance to EGFR-TKI shows diversification in clinical observation, therefore, close clinical follow-up is necessary for early attention and timely treatment.
authors.affiliation: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Lin
authors.initials: L
authors.lastname: Lin
authors.forename: Xuezhi
authors.initials: X
authors.lastname: Hao
authors.forename: Xiangru
authors.initials: X
authors.lastname: Zhang
authors.forename: Junling
authors.initials: J
authors.lastname: Li
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Shi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib